FoundationOne CDx:



FOUNDATIONONE® CDx

PATIENT Sample, ine | TUMOR TYPE Lung adenocarcinoma | REPORT DATE 01 Jan 2018 | QRF# XXXXXXXX

ABOUT THE TEST FoundationOne®CDx is a next-generation sequencing (NGS) based assay that identifies genomic findings within hundreds of cancer-related genes.

PATIENT
DISEASE Lung adenocarcinoma
NAME Not Given
DATE OF BIRTH Not Given
SEX Female
MEDICAL RECORD # Not Given

PHYSICIAN
ORDERING PHYSICIAN Not Given
MEDICAL FACILITY Not Given
ADDITIONAL RECIPIENT Not Given
MEDICAL FACILITY ID Not Given
PATHOLOGIST Not Given

SPECIMEN
SPECIMEN SITE Not Given
SPECIMEN ID Not Given
SPECIMEN TYPE Not Given
DATE OF COLLECTION Not Given
SPECIMEN RECEIVED Not Given

Biomarker Findings
Tumor Mutational Burden - TMB-Intermediate (11 Muts/Mb)
Micror

Genomic Findings
For a complete list of the genes assayed, please refer to the Appendix.
EGFR amplification, L858R
PTCH1 T416S
CDKN2A/B loss
RBM10 Q494*
TP53 R267P

7 Disease relevant genes with no reportable alterations: *KRAS, ALK, BRAF, MET, RET, ERBB2, ROS1*

14 Therapies with Clinical Benefit | 18 Clinical Trials
0 Therapies with Lack of Response

BIOMARKER FINDINGS	THERAPIES WITH CLINICAL BENEFIT (IN PATIENT'S TUMOR TYPE)	THERAPIES WITH CLINICAL BENEFIT (IN OTHER TUMOR TYPE)
Tumor Mutational Burden - TMB-Intermediate (11 Muts/Mb)	Atezolizumab Durvalumab Nivolumab Pembrolizumab	Avelumab
9 Trials see p. 14		
Microsatellite st tus - MS-Stable	No therapies or clinical trials. see Biomarker Findings section	

GENOMIC FINDINGS	THERAPIES WITH CLINICAL BENEFIT (IN PATIENT'S TUMOR TYPE)	THERAPIES WITH CLINICAL BENEFIT (IN OTHER TUMOR TYPE)
***EGFR* -** amplification, L858R	Afatinib Erlotinib Gefitinib Osimertinib	Cetuximab Lapatinib Panitumumab
4 Trials see p. 16		
***PTCH1* -** T416S	None	Sonidegib Vismodegib
5 Trials see p. 17		

GENOMIC FINDINGS WITH NO REPORTABLE THERAPEUTIC OR CLINI L TRIALS OPTIONS

For more information regarding biological and clinical significance, including prognostic, diagnostic, germline, and potential chemosensitivity implications, see the Genomic Findings section.

CDKN2A/B - loss ..... p. 5
RBM10 - Q494* ..... p. 5
TP53 - R267P ..... p. 6

NOTE Genomic alterations detected may be associated with activity of certain approved therapies; however, the agents listed in this report may have varied clinical evidence in the patient's tumor type. Therapies and the clinical trials listed in this report may not be complete and exhaustive. Neither the therapeutic agents nor the trials identified are ranked in order of potential or predicted efficacy for this patient, nor are they ranked in order of level of evidence for this patient's tumor type. This report should be regarded and used as a supplementary source of information and not as the single basis for the making of a therapy decision. All treatment decisions remain the full and final responsibility of the treating physician and physicians should refer to approved prescribing information for all therapies.

Therapies contained in this report may have been approved by the US FDA.

Electronically Signed by Julia A. Elvin, M.D., Ph.D. • Jeffrey S. Ross, M.D., Medical Director • 30 November 2017
Foundation Medicine, Inc. • 1-888-988-3639

Sample Preparation: 150 Second St., 1st Floor, Cambridge, MA 02141 • CLIA: 22D2027531
Sample Analysis: 150 Second St., 1st Floor, Cambridge, MA 02141 • CLIA: 22D2027531

PAGE 1 of 23

1. **Biomarkers findings**
   TMB and MSI status, which may predict response to immunotherapy
2. **Genomic findings**
   Clinically-relevant alterations in 324 tested cancer-related genes
3. **Pertinent negative results**
   Rules out important alterations that are not present
4. **Therapies with clinical benefit**
   Approved therapies for your patient's biomarkers and genomic alterations
5. **Clinical trials**
   Relevant trials that your patient may be eligible for, based on their genomic profile and geographic location
6. **Alterations with no reportable options**
   To help you rule out uncertainty and determine the most appropriate course of action

Roche Romania SRL
3-5 Piata Presei Libere, 1st District
City Gate - South Tower
Bucharest, 013702

FOUNDATION MEDICINE® | Roche